Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGNW), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (TVGNW) is a clinical-stage biotechnology company pioneering AI-driven precision T cell therapies for infectious diseases, cancers, and neurological disorders. This page serves as the definitive source for official company announcements, research breakthroughs, and strategic developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapeutic advancements, financial results, intellectual property updates, and leadership changes.
Key focus areas include Tevogen's innovative use of CD8+ cytotoxic T lymphocytes, developments in its Tevogen.AI platform, and strategic collaborations enhancing its immunotherapy pipeline. The news archive provides chronological tracking of the company's progress in creating accessible off-the-shelf treatments.
Bookmark this page for direct access to verified information about TVGNW's scientific advancements and corporate updates. Check regularly for new developments in precision immunotherapy and AI-enhanced drug discovery.
Tevogen has issued important guidance to its public shareholders regarding the differences between Direct Registration System (DRS) accounts and traditional brokerage accounts. The company, traded on Nasdaq under TVGN, highlights key distinctions between these account types to help investors make informed decisions.
Key differences include:
- DRS accounts register shares directly in the shareholder's name, offering direct control
- DRS may provide reduced transaction and maintenance costs
- Brokerage accounts offer enhanced trading tools
- Brokerage accounts typically enable faster share selling
- Transfer fees may apply when moving shares between account types
Shareholders interested in learning more about these options can contact Continental Stock Transfer & Trust, Tevogen's transfer agent, for detailed information.
Tevogen Bio CEO Dr. Ryan Saadi will join a key panel discussion at BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025. The panel, "Paths to Liquidity: Strategies for Adapting to a Volatile Market," will feature experts from J.P. Morgan, RSM, and Cantor Fitzgerald.
The conference, hosted at The Liberty Science Center in Jersey City, NJ, aims to connect investors, business development professionals, and industry executives to boost strategic partnerships and funding opportunities. The event includes:
- One-on-one partnering sessions
- Company pitch presentations
- Industry Connections Desk
- Exhibits and networking opportunities
- Plenary discussions
Dr. Saadi emphasized the critical timing of addressing market volatility and its impact on patient outcomes, aligning with Tevogen's mission to improve access to affordable lifesaving treatments.
Tevogen has reaffirmed its ambitious revenue projections for its oncology pipeline, forecasting $1 billion in launch year revenue and $10-14 billion in cumulative revenue over five years.
The company recently secured an agreement with CD 8 Technology Services providing up to $50 million for R&D and manufacturing facilities without impacting shareholder equity. This development aligns with Tevogen's business model focused on efficient drug development and patient accessibility.
CEO Ryan Saadi expressed confidence in the company's progress, particularly highlighting:
- Secured intellectual property
- Expanding U.S.-based cell therapy manufacturing
- Upcoming updates on forecasts and internal assets valuation
The company's strategy emphasizes sustainable medical innovation through a faster, cost-efficient development model, positioning itself in the cell therapy and oncology markets.
Tevogen Bio Holdings (Nasdaq: TVGN) has announced its 2025 Annual Meeting, scheduled for June 23, 2025, at 11 a.m. Eastern Time via live webcast. Stockholders of record as of April 30, 2025, will vote on two key matters: the re-election of two incumbent director nominees and the ratification of the company's independent registered public accounting firm.
The company will distribute proxy materials to stockholders, including voting instructions. Shareholders must provide their 16-digit control number found on their Notice of Internet Availability, proxy card, or voting instruction form to participate in voting. Meeting results will be disclosed via Form 8-K following the event.
Tevogen Bio (TVGN) has signed an agreement with CD 8 Technology Services for developing a turn-key facility supporting in-house pre-clinical research and GMP cell therapy production capabilities. The agreement has an initial 12-month term with automatic renewal.
The facility will be primarily staffed and operated by Tevogen Bio, marking a strategic move to accelerate development timelines, maintain operational agility, and control costs. The company expects this agreement to help overcome typical capital barriers in building GMP capabilities at scale.
The agreement formalizes a previously announced letter of intent with CD8, a company associated with Dr. Manmohan Patel, who owns over 5% of Tevogen's common stock. Specific details including scope of work, costs, and timelines will be outlined in future work orders.
Tevogen Bio (TVGN) has commissioned Databricks to accelerate the development of PredicTcell, their proprietary AI-driven target prediction model for precision immunotherapy. The collaboration will leverage Databricks' expertise in data engineering and AI systems to enhance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and TCR engagement prediction.
The partnership focuses on developing two foundational models based on Tevogen's ExacTcell™ platform: predicting immunologically active peptides through machine learning and creating a predictive T cell receptor binding model. This marks the third pillar of Tevogen.AI, alongside Microsoft Research providing digital infrastructure and AI expertise, while Tevogen Bio leads clinical and immunological science strategy.
Tevogen Bio Holdings (Nasdaq: TVGN) announces CEO Dr. Ryan Saadi's participation in BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025, at The Liberty Science Center in Jersey City. Dr. Saadi will join a panel discussion titled 'Paths to Liquidity: Strategies for Adapting to a Volatile Market,' alongside executives from J.P. Morgan, RSM, and Cantor Fitzgerald.
The conference aims to connect investors, BD professionals, academic collaborators, and biopharmaceutical industry executives to promote strategic partnerships, funding opportunities, and healthcare innovation. The event features 1:1 partnering sessions, company pitch presentations, Industry Connections Desk, exhibits, and networking opportunities.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced the launch of Tevogen Generics, a new initiative aimed at domestic manufacturing of unbranded pharmaceuticals and APIs. This effort aligns with President Trump's recent tariff-related statements and national focus on pharmaceutical affordability.
The company has appointed Sadiq Khan, MBA, the current Chief Commercial Officer, as Interim Head of this new venture. Tevogen Generics becomes the company's third strategic pillar, alongside:
- Tevogen Bio - specialty immunotherapy biotech focusing on off-the-shelf, precision T cell therapies
- Tevogen.AI - utilizing artificial intelligence for drug discovery and healthcare delivery optimization
- Tevogen Generics - focused on making essential medicines accessible
Tevogen Bio Holdings (Nasdaq: TVGN) participated in the AI x Bio Philly event, showcasing the intersection of artificial intelligence and life sciences in Philadelphia. Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, presented alongside leaders from BioCurie, BioPhy AI, and Proscia during the AI Demos and Presentations session.
Mehta's presentation highlighted Tevogen.AI's proprietary AI technology, which aims to accelerate the development of off-the-shelf precision T cell therapies through computational modeling of T cell receptor (TCR) engagement with immunologically active HLA+ peptide complexes. The event was hosted by BioBuzz, BitsInBio, Atria, and Zetta, bringing together innovators, entrepreneurs, and investors in the biotechnology sector.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced that company insiders, including executive officers and board members, currently hold approximately 74% of outstanding shares as of April 7, 2025. This significant insider ownership demonstrates management's confidence in the company's progress and potential.
The healthcare company operates in two main areas: immunotherapy through Tevogen Bio, which develops off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers, and artificial intelligence through Tevogen.AI, focused on enhancing drug discovery, clinical trial efficiency, and patient access. The company operates solely in the U.S. and maintains a tariff-insensitive position amid current market volatility.
CEO Dr. Ryan Saadi highlighted that insiders have only sold shares to satisfy tax obligations related to restricted stock vesting, further emphasizing their commitment to the company's mission of redefining the future of medicine.
FAQ
What is the current stock price of Tevogen Bio (TVGNW)?
